Yunus Emre Altuntaş

Prof. Yunus Emre Altuntaş

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2012 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
CGCem Gezen
Cem Gezen
MKMetin Kement
Metin Kement
YAYunus Emre Altuntaş
Yunus Emre Altuntaş
NONuri Okkabaz
Nuri Okkabaz
MSMesut Seker
Mesut Seker
MOMustafa Oncel
Mustafa Oncel
Locally advanced colorectal cancers are best treated with multivisceral resections. The aim of this study is to evaluate early and late results after multivisceral resections. All patients operated for primary colorectal cancer between 2001 and 2010 were -reviewed. These were compared within the patients underwent single organ and multivisceral resections: demographics, tumor and procedure related parameters, perioperative results, early oncological outcomes and 5-year survival. A total of 354 patients (59.6 ± 13.8 years old, 210 [59.3%] males) were abstracted. Ninety (25.4%) patients underwent multivisceral resections for clinical T4 tumors and en-bloc R0 resection was achieved in 82 (91.1%). Only 31 (34.4% and 8.8% of clinical T4 and all cancers, respectively) cases had actual adjacent organ invasions (pT4). Males (20%) had lower risk for locally advanced tumors than females (33.3%) (p < 0.05). PT4 cancers were more common, if the clinical T4 tumor is located in the colon (48.8% vs 21.3%; p < 0.01). Laparoscopy was seldom initiated and the risk of conversion was higher in clinical T4 tumors (p < 0.05). The rates of sphincter-saving procedures were not different. Operation time, bleeding and transfusion requirements increased when multivisceral resections were necessitated (p < 0.05), but hospital stay, complications and 30-day mortality rates were similar. The 5-year survival rates were identical (p > 0.05). Clinical T4 tumors are not rare and more common in women. An actual invasion (pT4) may be observed in one third of all clinical T4 tumors, and more frequent in colon cancers. An en-bloc, R0, multivisceral resection may be achieved in most cases. Multivisceral resections do not alter the rates of sphincter-saving procedures, morbidity and 30-day mortality; do not worsen survival but increase operation time, intraoperative bleeding and perioperative transfusion requirements.

1 January 2017 in Northern Clinics of Istanbul
Verified
Journal Article
Open access
YAYunus Emre Altuntaş
Yunus Emre Altuntaş
This study aimed to reveal the risk factors and outcomes of gallbladder perforation (GP) during laparoscopic cholecystectomy. Videotapes of all patients who underwent an elective cholecystectomy at our department were retrospectively analyzed, and the patients were divided into two groups based on the presence of GP. The possible risk factors and early outcomes were analyzed. In total, 664 patients [524 (78.9%) females, 49.7±13.4 years of age] were observed, and GP occurred in 240 (36.1%) patients, mostly while dissecting the gallbladder from its bed (n=197, 82.1%). GP was not recorded in the operation notes in 177 (73.8%) cases. Among the studied parameters, there was no significant risk factor for GP, except preoperatively elevated alanine transaminase level (p=0.005), but the sensitivity and specificity of this measure in predicting GP were 14.2% and 7.4%, respectively. The two groups had similar outcomes, but the operation time (35.4±17.5 vs 41.4±18.7 min, p=0.000) and incidence of drain use (25% vs 45.8%, p=0.000) increased in the GP group. The present study reveals that GP occurs in 36.1% of patients who undergo laparoscopic elective cholecystectomy, but it may not be recorded in most cases. We did not find any reliable risk factor that increases the possibility of GP. GP causes an increase in the operation time and incidence of drain use; however, the other outcomes were found to be similar in patients with GP and those without.

27 November 2025 in Metabolites
Verified
Journal Article
Open access
PDF file
IEISMAIL ERTUGRUL
ISMAIL ERTUGRUL
AÇAyşe Büşranur Çelik
Ayşe Büşranur Çelik
MUMervenur USLU
Mervenur USLU
MDMustafa Duman
Mustafa Duman
YAYunus Emre Altuntaş
Yunus Emre Altuntaş
YTYusuf Tutar
Yusuf Tutar
Background/Objective: Colon cancer, the third most diagnosed cancer worldwide, is anatomically classified into right- and left-sided colon cancers based on embryonic origin and vascular supply. The aim of this study was to investigate molecular differences between patients with right- and left-sided colon cancer. Methods: In this pilot study, Blood samples from right-sided (n = 6) and left-sided (n = 6) colon cancer patients, as well as healthy controls (n = 6), were analyzed for 92 cancer-related genes via RT-qPCR. KEGG pathway analysis was performed with ShinyGO 0.82, and gene–metabolite interactions were assessed using EnrichR and MetaboAnalyst 6.0. Additionally, patients’ sociodemographic and clinical data were analyzed. Results: KEGG analysis revealed that p53, HIF-1, TNF, PI3K/Akt, MAPK, and Rap1 signaling pathways were enriched in right-sided colon cancer, whereas VEGF, HIF-1, MAPK, PI3K/Akt, Rap1, and Ras signaling pathways were implicated in left-sided colon cancer. In the gene–metabolite analysis, key metabolites identified in right-sided colon cancer included palmitic acid, adenosine triphosphate (ATP), glycerol, and adenosine diphosphate (ADP), associated with genes such as ACSL4, TP53, MAPK14, FLT1, AURKA, KDR, ERCC3, and PFKL. For left-sided colon cancer, glucose-6-phosphate (G6P), ATP, ADP, glycerol, and palmitoyl-CoA were key metabolites forming the basis of the gene–metabolite network, along with genes including G6PD, PFKL, MAPK14, FLT1, CDK4, AURKA, MAP2K1, ERCC3, TP53, WEE1, and GPD2. Conclusions: These findings highlight distinct molecular profiles between right- and left-sided colon cancers, particularly in pathways related to angiogenesis, apoptosis, ferroptosis, and fatty acid metabolism, which may inform therapeutic strategies.

2 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ÖİÖmer Faruk İnanç
Ömer Faruk İnanç
ŞKŞermin Çoban Kökten
Şermin Çoban Kökten
KÇKenan Çetin
Kenan Çetin
IEISMAIL ERTUGRUL
ISMAIL ERTUGRUL
WAWafi Attaallah
Wafi Attaallah
YAYunus Emre Altuntaş
Yunus Emre Altuntaş
Background: Recurrence of anal fistulas represents one of the most frequently encountered complications in fistula management and remains a dilemma. Studies investigating the histological structure of fistulas and their relationship with recurrence are extremely limited. Objective: To evaluate the specimens of anal fistulas for the presence of multinucleated giant cells and to assess whether any correlation existed between giant cell presence and fistula recurrence. Design: Prospective cohort study. Patients: Adult patients with intersphincteric perianal fistulas included. Patients with recurrent fistulas, Crohn’s disease, tuberculosis, malignancy, immunocompromised status, pregnancy, or those who declined surgical intervention were excluded. A total of 62 patients were included in the final analysis. Interventions: Fistulotomy and open biopsy taken from the fistula tract. Main Outcome Measures: Postoperative recurrence rates, presence of multinucleated giant cells in the sampled fistula tracts, and the association between giant cell presence and fistula recurrence. Results: After 6 months of follow-up, healing was achieved in 52 patients (84%), while fistula persistence was observed in 10 patients (16%) and considered as recurrence. Giant cells were significantly higher in the recurrence group, whereas age, gender, ASA score, and comorbidity did not differ significantly between recurrence and non-recurrence groups. Giant cell presence was observed in 3 patients (5.8%) without recurrence compared to 4 patients (40.0%) with recurrence (p = 0.01). Other histological markers showed no significant difference between the groups. Conclusions: Our study demonstrates that giant cell presence represents a significant predictor of recurrence in primary cryptoglandular intersphincteric anal fistula.